Nostrum Laboratories Inc. (Nostrum), located in Missouri and New Jersey, and its founder and CEO, Nirmal Mulye, Ph.D. (Mulye), have agreed to pay a minimum of $3,825,000, and up to $50 million if certain financial contingencies are met, to resolve allegations that they violated the False Claims Act by knowingly underpaying Medicaid rebates due for Nostrum’s drug Nitrofurantoin Oral Suspension (Nitro OS). The settlement is based on Nostrum’s and Mulye’s financial condition. Read More
Home » Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Related Posts
CEO of an Iranian Engineering Company Arrested for Allegedly Shipping
An Iranian national and U.S. lawful permanent resident has been arrested on a four-count federal indictment charging him with unlawfully exporting electronics used in railway… BronCEO of an Iranian Engineering Company Arrested for Allegedly Shipping
Air Force Employee Pleads Guilty to Conspiracy to Disclose Unlawfully
A civilian employee of the U.S. Air Force assigned to the U.S. Strategic Command (USSTRATCOM) at Offutt Air Force Base pleaded guilty today to conspiring… BronAir Force Employee Pleads Guilty to Conspiracy to Disclose Unlawfully
Two Former West Virginia Correctional Officers Sentenced on Federal
Two former correctional officers from the Southern Regional Jail in Beaver, West Virginia, were sentenced today for their roles in an assault that resulted in… BronTwo Former West Virginia Correctional Officers Sentenced on Federal